(Q34547861)

2 August 2017

1 reference

title

Fluoroquinolones as pneumococcal therapy: closing the barn door before the horse escapes (English)

1 reference

2 August 2017

G Tillotson

1

1 reference

2 August 2017

X Zhao

series ordinal

2

1 reference

2 August 2017

K Drlica

series ordinal

3

1 reference

2 August 2017

language of work or name

1 reference

1 October 2001

1 reference

Lancet Infectious Diseases

2 August 2017

1 reference

2 August 2017

1

1 reference

2 August 2017

3

1 reference

2 August 2017

145-146

1 reference

Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900090-1

7 January 2021

Fluoroquinolones in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900090-1

7 January 2021

Lower respiratory tract infection therapy--the role of ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900090-1

7 January 2021

Trends in bacterial resistance to fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900090-1

7 January 2021

Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900090-1

7 January 2021

A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900090-1

7 January 2021

Comparative pharmacokinetics and safety of ciprofloxacin 400 mg i.v. thrice daily versus 750 mg po twice daily

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900090-1

7 January 2021

Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900090-1

7 January 2021

In vitro activities of quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900090-1

7 January 2021

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900090-1

7 January 2021

Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900090-1

7 January 2021

Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900090-1

7 January 2021

Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900090-1

7 January 2021

Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900090-1

7 January 2021

10.1016/S1473-3099(01)00090-1

Identifiers

DOI

1 reference

2 August 2017

1 reference